All In Biotech

Drug Trial Radar · NCT07371429

A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics

Phase 1, Open-Label, Single Arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants From 2 to Less Than 12 Years of Age With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis With Antibiotics

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Sep 18, 2026

Primary completion

Aug 23, 2027

Study completion Aug 23, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment with antibacterials for a confirmed or suspected infection or for its prevention.

Conditions

  • Urinary Tract Infections

Interventions

  • GepotidacinDrug

    Gepotidacin will be administered

  • SOCDrug

    SOC will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC from time zero to the time of the last quantifiable concentration (AUC[0-t]) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
  2. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC[0-inf]) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
  3. Maximum observed plasma concentration (Cmax) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
  4. Apparent oral clearance (CL/F) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
  5. Apparent volume of distribution (Vz/F) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
  6. Terminal phase half-life (t1/2) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Orange, California

  • GSK Investigational Site

    Shreveport, Louisiana

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.